Senators Propose Bill to Crack Down on Drugmaker Rebate Abuse

Ron Wyden (D-Ore.) and Chuck Grassley (R-Iowa) proposed legislation Dec. 4, 2018, to prevent drug makers from saving on rebates by misclassifying their drugs in the Medicaid Drug Rebate Program. (www.wyden.senate.gov (L) www.grassley.senate.gov)

WASHINGTON—Two U.S. senators from opposite sides of the aisle are proposing legislation that would close a loophole in the Medicaid rebate program that allowed Mylan to save over a billion dollars by allegedly misclassifying the EpiPen.

Proposed by Ron Wyden (D-Ore.) and Chuck Grassley (R-Iowa), both members of the Senate Finance Committee, the bill would give the secretary of the Department of Health and Human Services (HHS) the authority to go after misclassifications made by drugmakers.